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Asha R. Patel,1 Maria L. Turner,1 Kristin Baird,2 Juan Gea-Banacloche,3 Sandra Mitchell,4
Steven Z. Pavletic,3 Barbara Wise,2 Edward W. Cowen1Systemic fungal infections pose a significant risk to patients following allogeneic hematopoietic cell transplan-
tation (alloHCT). Voriconazole (Vfend, Pfizer) is an oral second-generation triazole antifungal agent that
offers a broad spectrum of coverage against fungal species and is frequently utilized in the post-HCT setting.
Herein, we describe 5 patients who were initially believed to be experiencing a flare of cutaneous chronic
graft-versus-host disease (cGVHD), but who were actually exhibiting phototoxicity caused by voriconazole.
A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and
avoid inappropriate therapy for cGVHD.
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Systemic fungal infections pose a significant risk
to patients following allogeneic hematopoietic cell
transplantation (alloHCT). In the early posttransplant
period, neutropenia is the primary risk factor, and
frequently fluconazole is used as effective prophylaxis
against Candida infections. Late after engraftment,
however, the most important fungal infection is inva-
sive aspergillosis, particularly during periods of active
graft-versus-host disease (GVHD) and increased
corticosteroid use [1,2]. Voriconazole (Vfend, Pfizer,
New York), a second-generation oral triazole antifun-
gal agent, is the treatment of choice for invasive
aspergillosis [3], and its ease of administration and
favorable safety profile have resulted in increased utili-
zation as antifungal prophylaxis, especially when there
is high risk for aspergillosis [4]. Like the other azole
antifungals, voriconazole inhibits cytochrome P450-1Dermatology Branch; 2Pediatric Oncology Branch; 3Ex-
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6/j.bbmt.2008.12.491dependent14-a-sterol demethylase, which is required
for ergosterol biosynthesis, resulting in destruction
of the fungal plasma membrane. It is effective against
Aspergillus sp, molds, and yeasts [5].
Following FDA approval in 2001, expanded utili-
zation of voriconazole has led to increased recognition
of the drug’s potential side effects, which include vi-
sion changes (20%), hallucinations (15%), hepatic en-
zyme abnormalities (12%-20%), and skin reactions
(17%) [5]. In preliminary clinical studies, a photosensi-
tive rash was reported in only 2% of patients (41 of
2090) [5]. Herein, we describe 5 patients who were be-
lieved to be suffering from recalcitrant skin chronic
GVHD (cGVHD), but who were actually experienc-
ing cutaneous phototoxicity caused by voriconazole.
A high index of suspicion for this adverse reaction in
post-alloHCT patients will facilitate the proper diag-
nosis and avoid inappropriate therapy for cGVHD.
MATERIALS AND METHODS
In this retrospective analysis, 5 patients with
cGVHD who developed voriconazole-associated
phototoxicity were identified at the National Institutes
of Health (NIH) dermatology service between May
2003 and August 2007. Medical records, clinical pho-
tography, and histologic specimens were reviewed.
Patient characteristics are summarized in Table 1.
RESULTS
Patient 1 was a 15-year-old male diagnosed at age
6 with metastatic alveolar rhabdomyosarcoma. He
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Biol Blood Marrow Transplant 15:370-376, 2009 371Voriconazole-Induced Phototoxicityunderwent a matched nonmyeloablative allogeneic
peripheral blood hematopoietic cell transplantation
(alloPBHCT) following failure of multiple therapies.
Acute cutaneous GVHD (aGVHD) was confirmed by
skin biopsy on day18 posttransplant. Recurrent lichen
planus-like cGVHD was noted at day 1100, followed
by vitiligo 20months posttransplant (Figure 1A and B).
Thirty-two months posttransplant, voriconazole
was initiated for a presumed pulmonary aspergillosis.
Two months later, the patient developed bright
erythema of the forehead, malar cheeks, hands, fore-
arms, and arms, which his treating physicians attrib-
uted to a flare of skin cGVHD. At the time of his
NIH evaluation, several erosions and intact bullae
were also noted on the head, neck, arms, anterior
legs, and dorsal aspects of both feet (Figure 1C and D).
A diagnosis of phototoxicity and drug-induced
pseudoporphyria cutanea tarda (pseudo-PCT) second-
ary to voriconazole was made. Voriconazole was
replaced by posaconazole and strict photoprotection
was instituted. The bullae resolved in 3 weeks and
the erythema gradually dissipated.
Patient 2 was a 6-year-old female who underwent
a 5 of 6 mismatched unrelated myeloablative umbilical
cord blood transplantation for pre-B cell acute
lymphoblastic leukemia (ALL) 11 months before
presenting to the NIH. Two months posttransplant,
the patient developed biopsy-confirmed cutaneous
aGVHD that was treated with prednisone 30 mg/day
and that she continued to require for recurrent skin
flares. Voriconazole was initiated empirically 3months
posttransplant for pulmonary nodules identified on
computed tomography (CT) scan. Threemonths later,
the voriconazole dosage was increased from 125 mg
twice daily to 175 mg twice daily after new pulmonary
nodules were identified.
At the time of her NIH evaluation, patchy mac-
ular erythema and extensive macular pigmentation
(solar lentigines) were noted on photoexposed areas
of the body (Figure 2). These findings were consistent
with chronic photodamage. Two weeks following
replacement of voriconazole with posaconazole
and institution of strict photoprotection, the erythema
on photoexposed skin surfaces had faded to a light
pink.
Patient 3 was a 40-year-old female with relapsed
mediastinal, large B cell lymphoma resistant to chemo-
therapy and radiation, who underwent a matched
nonmyeloablative alloPBHCT.The patient developed
skin aGVHD on day 144 and progressive, treatment-
resistant sclerotic skin manifestations of cGVHD 15
months posttransplant. Voriconazole was instituted
3 years prior to the patient’s initial visit following
pulmonary aspergillosis.
Six years 5 months posttransplant, the patient
presented to the NIH with new bullae on brightly er-
ythematous and edematous sun-exposed areas of the
Figure 1. Patient 1 prior to voriconazole administration (A,B) and after treatment with 8 weeks of voriconazole 200 mg twice a day (C,D). Multiple
depigmented patches are present on the head and neck area (A) and accentuate upon visualization with Wood’s lamp (B), consistent with vitiligo; (C)
erythema and denuded bullae are present on the forehead, bilateral cheeks, nose, and chin; skin changes are most pronounced at sites of previous
depigmentation; (D) prominent erythema on the photoexposed surfaces of the forearms and distal arms with superficial sunburn-like desquamation.
372 Biol Blood Marrow Transplant 15:370-376, 2009A. R. Patel et al.upper and lower extremities as well as the V-area of the
neck. Three days prior to presentation, she spent sev-
eral hours at a picnic, reportedly primarily under the
shade of a tree. Vesicles, bullae, and papules were
noted on her hands and extensor forearms that evening
(Figure 3A). A 3-mm punch biopsy taken from the left
hand demonstrated epidermal necrosis most consis-
tent with a phototoxic drug reaction (Figure 3B).
The patient experienced marked improvement inFigure 2. Patient 2, following 11 months of treatment with voriconazole 175
dorsal surfaces of the hands and forearms suggestive of ongoing phototoxicity
pigmentation is present on the upper chest.erythema of photoexposed skin after switching from
voriconazole to posaconazole and strict photoprotec-
tion, but she continued to have erythematous and ero-
sive skin disease in the photoprotected areas, including
her abdomen and back. The prednisone dosage was
increased to 60 mg daily, and the patient received
rituximab weekly for 4 weeks in an attempt to control
the GVHD. Three months later, she died of pseudo-
monal sepsis.mg twice a day. Erythema and multiple round tan/brown macules on the
and chronic photodamage, respectively. Similar erythema and macular
Figure 3. (A) Patient 3 following 36 months of voriconazole 200 mg twice a day. The patient had ongoing cGVHD of the skin with erythema and
sclerosis, but developed acute exacerbation of erythema with new intact bullae formation after sun exposure; (B) skin biopsy demonstrates epidermal
necrosis at all levels associated with a moderately dense neutrophilic infiltrate (hematoxylin and eosin, 10 magnification).
Biol Blood Marrow Transplant 15:370-376, 2009 373Voriconazole-Induced PhototoxicityPatient 4 was a 47-year-old male who underwent
a matched related nonmyeloablative alloPBHCT for
chronic myelogenous leukemia (CML). One month
posttransplant, the patient developed cutaneous
a GVHD. Similar eruptions recurred over his torso
for the next several years. Thirty-one months post-
transplant, voriconazole was initiated for a presumed
pulmonary aspergillosis. Three months later the
patient presented to the NIH with an 8-week history
of coarse, erythematous to violaceous scaly, thickened
skin on his cheeks and posterior and lateral neck
(Figure 4). A 3-mm biopsy from the neck was sugges-
tive of cutaneous lupus. The antinuclear antibodyFigure 4. Patient 4 following 3 months of treatment with voriconazole
200 mg twice a day. Numerous erythematous/violaceous plaques on the
face.(ANA) titer was 5.4EU (0.0-0.9). Anti-ENA screen
and anti-ds DNA titers were negative. Voriconazole-
induced phototoxicity was diagnosed and the patient’s
antifungal treatment was changed to itraconazole.Figure 5. (A) Patient 5, following 4 months of treatment with vorico-
nazole 200 mg twice a day. Marked hyperpigmentation on the photoex-
posed surfaces of the face; (B) pigmentation is significantly improved 1
year later; (C) pathology demonstrated hyperkeratosis, acanthosis,
destruction of the basal epidermal layer with necrotic keratinocytes,
and a sparse lymphocytic infiltrate with frequent pigmented macro-
phages (hematoxylin and eosin, magnification 10).
374 Biol Blood Marrow Transplant 15:370-376, 2009A. R. Patel et al.Four months later, the skin erosions had resolved and
the violaceous discoloration improved significantly.
Patient 5was a 59-year-oldmale withmyelogenous
metaplasiaandmyelofibrosiswhounderwentamatched
nonmyeloablative alloPBHCT and presented to the
NIH 9 months posttransplantation. Additionally, 4
months posttransplantation the patient developed
biopsy proven hepatic GVHD. The following month
voriconazole was initiated for a presumed pulmonary
fungal infection. At the time of his evaluation, the
patient reported a 6-week history of asymptomatic
scaly plaques on sun exposed areas of the arms, neck,
scalp, and V-neck area of the upper chest (Figure 5A).
He described a recent increase in outdoor activity
following recovery from his pulmonary infection.
Biopsy from the left arm showed destruction of the
basal epidermal layer with necrotic keratinocytes, com-
patible with a diagnosis of GVHD or phototoxic drug
reaction (Figure 5C). Although this patient had
received voriconazole episodically in the ensuing few
months, the rash continued to improve (Figure 5B)
with the institution of strict photoprotection.DISCUSSION
Drug-induced photosensitivity may be photoaller-
gic or phototoxic. Phototoxic reactions do not require
prior exposure, and are dependent both on the dose of
drug and ultraviolet light (UVL) exposure. Thus,
a high dose of a photosensitizingmedication combined
with prolonged and or intense UVL exposure may re-
sult in erythema and edema resembling acute sunburn
[6]. RepeatedUVL exposure in patients on a photosen-
sitizing drug can simulate the effect of chronic actinic
damage with development of hyperpigmentation, dry
skin, and solar lentigines. Phototoxicity occurs when
the appropriate wavelength of light penetrates the
skin where the photosensitizing drug or its metabolite
is located. The photosensitizer absorbs the UVL
energy, inducing oxygen radical formation, followed
by cellular damage and an inflammatory response [7].
Pseudo-PCT represents a severe form of phototoxicity
with bullae formation resembling PCTwithout associ-
ated elevated blood porphyrin levels (Patient 1). Vori-
conazole is a known phototoxic agent [8-17], and it has
also been reported to induce pseudo-PCT [18-21].
In the 5 patients described, the diagnosis of photo-
toxicity was confounded by a history of cutaneous
cGVHD and the inability to reliably distinguish
between cGVHD and phototoxicity based on routine
histologic methods. We based the diagnosis of vorico-
nazole-induced phototoxicity on a number of clinical
features, including distinct photodistribution of skin
lesions, a history of UVL exposure contemporaneous
with drug administration, the absence of signs of
reactivation of GVHD in other organ systems, andimprovement of skin lesions upon discontinuation of
voriconazole and/or institution of strict photoprotec-
tion. Although biopsies were performed in 3 cases,
the histopathologic findings of phototoxicity, includ-
ing necrotic or apoptotic keratinocytes in various
layers of the epidermis, vacuolization of the cells in
the basal layer, and a mild superficial perivascular lym-
phohistiocytic infiltrate may also be observed in exan-
thematous GVHD. Similarly, the presence of
epidermal necrosis is reflected in the severity of both
GVHD and phototoxicity, and cannot definitively sep-
arate either disease process [22-24]. Even the presence
of eosinophils in the dermal infiltrate, a frequent find-
ing in cutaneous drug reactions, does not reliably dis-
tinguish between phototoxic drug reactions and
GVHD [22,25]. As exacerbations of cutaneous
cGvHDmay be triggered by both phototoxic and non-
phototoxic drug eruptions, careful monitoring for per-
sistent skin symptoms is warranted following
identification and discontinuation of the causative
agent.
Although voriconazole has been available for
a number of years and is frequently used for prophy-
laxis [4], it is not yet approved for this indication. Pos-
aconazole, a recently approved orally bioavailable
antifungal, has been shown to prevent invasive asper-
gillosis in patients at high risk for infection, including
patients with severe aGVHDor cGVHDon treatment
with corticosteroids [26]. Posaconazole has proven to
be effective in patients with systemic mycosis refrac-
tory to voriconazole or who develop intolerable side
effects with voriconazole [27]. It has broad-spectrum
activity against Candida, Aspergillus, and Zygomycetes
species [28,29]. Posaconazole-associated photosensi-
tivity has not been described in the literature, and we
have not observed it in our cGVHD patients.
In our experience, the incidence of phototoxicity
associated with voriconazole in the post-HCT setting
is significantly higher than that reported in the initial
clinical trial data. Whereas the initial voriconazole
clinical trials enrolled hospitalized patients, our NIH
population consisted primarily of outpatients with
greater opportunity for exposure to UVL.
Because UVL exposure may induce a flare of cuta-
neous cGVHD independent of concurrent phototoxic
drug exposure [30,31], sun avoidance and photoprotec-
tion are recommended for all patients evaluated in our
cGVHD clinic. Furthermore, patients with cGVHD
are often exposed to other potential photosensitizing
agents in addition to voriconazole, including trimeth-
oprim/sulfamethosazole, hydrochlorthiazide, and fu-
rosemide. Specific recommendations include sun
avoidance at peak hours, use of protective clothing,
and liberal application of both physical and chemical
sunblocks that absorb bothUV-A andUV-B radiation.
Laundry rinse-cycle additives are also available to
increase the UV protective factor of clothing [30].
Biol Blood Marrow Transplant 15:370-376, 2009 375Voriconazole-Induced PhototoxicityAlthough the exact incidence of cutaneous drug
reactions (CDR) is difficult to quantify, they are
among the most frequent adverse drug reactions,
accounting for approximately 10% to 20% of all
reported adverse events. CDRs are most consistently
associated with exposure to antimicrobial agents, in-
cluding sulfonamides, flouroquinolones, penicillins,
and cephalosporins [32,33]. The most common CDR
is a morbilliform rash, characterized by fine pink mac-
ules and papules on the trunk, which eventually coa-
lesce and spread to the extremities. Skin lesions
typically begin 1 to 2 weeks following drug exposure
and fade slowly following discontinuation. By contrast,
urticarial hypersensitivity reactions usually develop
within 1 to 2 days of drug initiation, and individual le-
sions resolve within 24 hours. The most worrisome
CDRs are erythemamultiforme/Stevens-Johnson syn-
drome/toxic epidermal necrolysis, a spectrum of severe
drug hypersensitivity with variable skin involvement
ranging from localized dusky targetoid plaques to
widespread skin sloughing with mucosal membrane
involvement and significant associated mortality.
Often symptoms of a severe CDR do not present until
several weeks after initial drug exposure [34].
Attention to the details of the clinical presentation
and the drug administration history are of utmost
importance in establishing the correct diagnosis in
patients with cGVHD, given their complex medical
history and the high likelihood of polypharmacy. In
this setting, when confronted with a new onset erup-
tion that is not considered diagnostic of cGVHDbased
onNIH consensus criteria [35], helpful clinical criteria
in defining a CDR include: (1) exclusion of other
causes for the eruption, such as viral exanthem; (2)
identification of a temporal relationship between
drug use and onset of the rash; (3) improvement fol-
lowing drug cessation; and reactivation of the rash
upon rechallenge (if performed) [36].
As voriconazole has become a frequent choice for
antifungal prophylaxis and treatment in the setting of
alloHCT, the possibility of voriconazole-induced
phototoxicity should be considered in all new skin
eruptions, even those that simulate a flare of cutaneous
cGVHD in patients with known cutaneous cGVHD.
The recognition of voriconazole phototoxicity is espe-
cially important as efficacious treatment alternatives
are readily available, and accurate diagnosis of photo-
toxic drug reaction will prevent misdiagnosis of
cGVHD and unnecessary immunosuppression.ACKNOWLEDGMENTS
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